ProCE Banner Activity

CME

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance to Refine Clinical Management Strategies

Multimedia
Learn how experts leverage BTK inhibitors for optimal management of patients with MCL, CLL, and other B-cell malignancies in this CME-certified, on-demand Webcast of a dynamic CCO symposium at ASH 2019.

Physicians: Maximum of 2.75 AMA PRA Category 1 Credits

Released: February 04, 2020

Expiration: February 03, 2021

No longer available for credit.

Share

Faculty

Jan A. Burger

Jan A. Burger, MD, PhD

Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Alexey Danilov

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

Ian Flinn

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

John Pagel

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Target Audience

This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Plan optimal, individualized therapeutic strategies for patients with MCL, CLL/SLL, WM and other B-cell malignancies taking into consideration recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Seattle Genetics, TG Therapeutics, and Verastem Oncology and funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno, Karyopharm, Kite Pharma, Merck, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem Oncology.

Faculty Disclosure

Primary Author

Jan A. Burger, MD, PhD

Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jan A. Burger, MD, PhD, has disclosed that he has received funds for research support from BeiGene, Gilead Sciences, and Pharmacyclics and speakers’ fees from Janssen.

Alexey Danilov, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Knight Cancer Institute
Oregon Health and Science University
Portland, Oregon

Alexey Danilov, MD, has disclosed that he has received funds for research support from Aptose Bio, AstraZeneca, Bayer Oncology, Bristol-Myers Squibb, Genentech, Gilead Sciences, MEI Pharma, Takeda Oncology, and Verastem Oncology and consulting fees from AstraZeneca, BeiGene, Celgene, Curis, Genentech, Gilead Sciences, Janssen, Juno, Pharmacyclics, Teva Oncology, TG Therapeutics, and Verastem Oncology.

John Pagel, MD, PhD

Associate Professor
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

John Pagel, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Gilead Sciences, and Pharmacyclics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 04, 2020, through February 03, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in selecting and safely integrating BTK inhibitors within the current treatment paradigm for various B-cell malignancies considering patient-specific and prognostic factors as well as appropriate dosing and strategies to manage treatment-emergent adverse events.